Clinical Trial Update: Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics, safety and tolerability study of BIIL 284 BS in patients with hepatic insufficiency compared to healthy volunteers. The trial assesses…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Insufficiency

Drugs mentioned

• BIIL 284 BS

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatic Insufficiency | Phase 1 | Status: COMPLETED